Olimestra (Olmesartan Medoxomil)

Olimestra is an angiotensin‑blocking agent used in the management of cardiovascular conditions that involve the renin‑angiotensin system.

• Hypertension: helps lower systolic and diastolic blood pressure to target levels.
• Heart failure: used as part of combination therapy to improve cardiac output and reduce hospitalisation risk.
• Diabetic nephropathy: slows progression of kidney damage by controlling blood pressure.
• Post‑myocardial infarction: assists in long‑term blood‑pressure control to reduce strain on the healing heart.
• Stroke prevention: contributes to secondary prevention by maintaining optimal blood pressure.
• Chronic kidney disease: aids in preserving renal function through sustained blood‑pressure control.

• Olmesartan medoxil is a pro‑drug that is converted to olmesartan, which selectively blocks the binding of angiotensin II to the AT‑1 receptors on vascular smooth‑muscle and adrenal cells. This inhibition prevents vasoconstriction and aldosterone release, leading to relaxation of blood vessels, reduced peripheral resistance, and lower blood pressure.

Olimestra may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Nasal congestion
• Diarrhoea
• Cough

Serious or Rare Side Effects

• Angio‑edema involving the face, lips or tongue
• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Liver enzyme elevation
• Allergic skin reactions such as Stevens‑Johnson syndrome

When prescribing Olimestra, clinicians should consider several safety aspects.

• Blood pressure monitoring: check baseline and periodic readings to avoid excessive fall.
• Renal function assessment: evaluate creatinine and eGFR before initiation and during therapy.
• Electrolyte surveillance: monitor serum potassium, especially if combined with potassium‑sparing agents.
• Pregnancy contraindication: avoid use in pregnancy due to fetal toxicity.
• Drug‑interaction review: assess concurrent medications that affect the renin‑angiotensin system.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olimestra can interact with several medicines that influence blood pressure, renal function or electrolyte balance.

Major Interactions (Avoid)

• Dual renin‑angiotensin blockade (e.g., ACE inhibitors, other ARBs): risk of severe hypotension, hyperkalaemia, renal impairment.
• Potassium‑rich supplements or potassium‑sparing diuretics: may cause dangerous hyperkalaemia.
• Aliskiren in diabetic patients: increased risk of renal dysfunction and hypotension.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect kidney function.
• Diuretics (thiazides): may enhance hypotensive response.
• Lithium: may increase lithium levels, risking toxicity.
• Antacids containing aluminium or magnesium: may reduce olmesartan absorption.
• Rifampicin: may lower olmesartan plasma concentrations.